Immutep ($IMMP) TACTI-004 Phase III Lung Cancer Trial Safety and Efficacy Case

Investors can submit applications for the lead plaintiff role.

S.D. New York

Court

1:26-cv-03705

Case number

03/24/2025

Class period Start

03/12/2026

Class period End

07/06/2026

Lead Plaintiff motion deadline

$IMMP investors filed a claim against Immutep for overstating the outlook for its TACTI-004 Phase III lung cancer trial while allegedly concealing risks that the study could fail its interim review.
After Immutep announced that the trial monitor recommended discontinuing TACTI-004 for futility, $IMMP fell 82.6% on March 13, 2026, closing at $0.48 per share.
$IMMP investors can join this case to be notified about potential recovery.
Case Details:

Between March 24, 2025 and March 12, 2026, Immutep told investors that its TACTI-004 Phase III trial was evaluating efti with KEYTRUDA and chemotherapy as a first-line treatment for advanced or metastatic non-small cell lung cancer. Executives emphasized that prior TACTI-002 and INSIGHT-003 results showed strong efficacy, an excellent safety profile, durable responses, and encouraging survival data, while describing TACTI-004 enrollment as strong and on track.

However, during this period, investors allege Immutep’s internal trial information showed a greater risk that TACTI-004 would not succeed. Immutep allegedly failed to disclose available safety and efficacy data, which increased the risk that TACTI-004 would fail its interim futility review; positive results from earlier efti studies did not reliably show that TACTI-004 would meet its goals, and the company was minimizing risks tied to the trial’s efficacy, safety, and future viability.

Then, on March 13, 2026, Immutep revealed that the Independent Data Monitoring Committee recommended discontinuing TACTI-004 after reviewing available safety and efficacy data during a planned interim futility analysis. 

$IMMP fell $2.28, closing at $0.48. By March 13, 2026, shares had dropped from $2.76 to $0.48, representing a total decline of 82.6% over the correction period.

Based on these events, $IMMP investors filed a claim against Immutep, alleging the company:
It overstated TACTI-004’s prospects.
It used earlier efti study results to support confidence in TACTI-004 while allegedly hiding trial-specific risks.
It left investors unprepared for the trial’s discontinuation and the collapse in the ADR price.
Investors argue Immutep misled the market about the safety, efficacy, and viability of TACTI-004, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Fraud,

Failure to Disclose

Suspected Party

Directors,

Management

Security Type

Depository Securities (ADS, ADR, GDR)

Trade Direction

Long

Shock Event Date

03/13/2026

Filing date

05/05/2026

Lead Plaintiff Deadline

07/06/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.